NCT04740970Phase 2Withdrawn🇫🇷 With a site in France
A Study of JNJ-64304500 in Participants With Alopecia Areata
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-64304500 in Patients With Alopecia Areata
In the register
The register attaches this trial to Tesnatilimab (JNJ-64304500) (Johnson & Johnson), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Withdrawn
- Declared phase
- Phase 2
- Sponsor
- Janssen Research & Development, LLC
- Participants (registry)
- —
- Start
- March 2021 (planned)
- Primary completion
- June 2022
- Study completion
- July 2022
- Last registry update
- May 2021
- Countries
- United States, Australia, France, Japan
Conditions studied: Alopecia Areata
Interventions: JNJ-64304500, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.